만성신장병(CKD) 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Chronic Kidney Disease Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487515
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 143 Pages
라이선스 & 가격 (부가세 별도)
한글목차
만성신장병(CKD) 치료제 시장 - 조사 범위
TMR의 조사 보고서 "세계 만성 신장 질환(CKD) 치료제 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 만성신장병(CKD) 치료제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 만성신장질환(CKD) 치료제 시장의 연평균 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 조사 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료 및 관련 문서를 참조하여 만성 신장 질환(CKD) 치료제 시장을 이해하고자 했습니다. 관련 문서를 참고했습니다.
시장 현황
2023년 시장 규모
148억 달러
2034년 시장 가치
238억 달러
CAGR
4.2%
이 보고서는 세계 만성신장병(CKD) 치료제 시장의 경쟁 환경을 조사했습니다. 세계 만성신장병(CKD) 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 세계 만성 신장 질환(CKD) 치료제 시장의 기업들이 이 보고서에서 제공하는 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
시장 개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19 팬데믹 업계에 대한 영향
제6장 세계 시장 분석과 예측 : 약제 클래스별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 약제 클래스별, 2020-2034
ACE 억제제
안지오텐신 II 수용체 길항제
칼슘 채널 차단제
베타차단제
적혈구 조혈 자극인자 제제(ESAs)
이뇨제
기타
시장의 매력 분석 : 약제 클래스별
제7장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 최종사용자별, 2020년-2034년
병원
전문 클리닉
시장의 매력 분석 : 최종사용자별
제8장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020년-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별·기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi
GSK plc
Kissei Pharmaceutical Co., Ltd.
AbbVie Inc.
Akebia Therapeutics, Inc.
AstraZeneca
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
LSH
영문 목차
영문목차
Chronic Kidney Disease (CKD) Drugs Market - Scope of Report
TMR's report on the global chronic kidney disease (CKD) drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global chronic kidney disease (CKD) drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic kidney disease (CKD) drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the chronic kidney disease (CKD) drugs market.
Market Snapshot
Market Value in 2023
US$ 14.8 Bn
Market Value in 2034
US$ 23.8 Bn
CAGR
4.2%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global chronic kidney disease (CKD) drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global chronic kidney disease (CKD) drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global chronic kidney disease (CKD) drugs market.
The report delves into the competitive landscape of the global chronic kidney disease (CKD) drugs market. Key players operating in the global chronic kidney disease (CKD) drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global chronic kidney disease (CKD) drugs market profiled in this report.
Key Questions Answered in Global chronic kidney disease (CKD) drugs Market Report:
What is the sales/revenue generated by chronic kidney disease (CKD) drugs across all regions during the forecast period?
What are the opportunities in the global chronic kidney disease (CKD) drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Chronic Kidney Disease (CKD) Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global chronic kidney disease (CKD) drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global chronic kidney disease (CKD) drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global chronic kidney disease (CKD) drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. ACE Inhibitors
6.3.2. Angiotensin-II Receptor Blockers
6.3.3. Calcium Channel Blockers
6.3.4. Beta Blockers
6.3.5. Erythropoiesis-stimulating Agents (ESAs)
6.3.6. Diuretics
6.3.7. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.4. Market Attractiveness Analysis, by End-user
8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
9.3.1. ACE Inhibitors
9.3.2. Angiotensin-II Receptor Blockers
9.3.3. Calcium Channel Blockers
9.3.4. Beta Blockers
9.3.5. Erythropoiesis-stimulating Agents (ESAs)
9.3.6. Diuretics
9.3.7. Others
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By End-user
9.6.3. By Country
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. ACE Inhibitors
10.3.2. Angiotensin-II Receptor Blockers
10.3.3. Calcium Channel Blockers
10.3.4. Beta Blockers
10.3.5. Erythropoiesis-stimulating Agents (ESAs)
10.3.6. Diuretics
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. ACE Inhibitors
11.3.2. Angiotensin-II Receptor Blockers
11.3.3. Calcium Channel Blockers
11.3.4. Beta Blockers
11.3.5. Erythropoiesis-stimulating Agents (ESAs)
11.3.6. Diuretics
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. ACE Inhibitors
12.3.2. Angiotensin-II Receptor Blockers
12.3.3. Calcium Channel Blockers
12.3.4. Beta Blockers
12.3.5. Erythropoiesis-stimulating Agents (ESAs)
12.3.6. Diuretics
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. ACE Inhibitors
13.3.2. Angiotensin-II Receptor Blockers
13.3.3. Calcium Channel Blockers
13.3.4. Beta Blockers
13.3.5. Erythropoiesis-stimulating Agents (ESAs)
13.3.6. Diuretics
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
